All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche and sobi, and supported through educational grants from Bristol Myers Squibb, Incyte and Lilly. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
SYMPATICO: Ibrutinib plus venetoclax in relapsed/refractory MCL
|
The combination of ibrutinib, a BTK inhibitor, and venetoclax, a BCL-2 inhibitor, has shown efficacy in MCL in early clinical trials.1 Results from the phase III SYMPATICO trial (NCT03112174) evaluating the efficacy and safety of ibrutinib-venetoclax in R/R MCL were published in The Lancet Oncology by Wang et al.1 A total of 267 patients were randomly assigned to receive ibrutinib-venetoclax (n = 134) or ibrutinib-placebo (n = 133).1 The primary endpoint was investigator-assessed PFS in the intention-to-treat population.1 |
| Key learnings |
| The ibrutinib-venetoclax group had a significantly longer median PFS (31.9 months vs 22.1 months; HR, 0.65; 95% CI, 0.47–0.88; p = 0.0052) and a higher estimated 24-month PFS rate (57% vs 45%) than the ibrutinib-placebo group. |
| The CRR was significantly higher in the ibrutinib-venetoclax vs ibrutinib-placebo group (54% vs 32%; p = 0.0004). The ORR was 82% vs 74%, with the median TTNT not reached vs 35.4 months (HR, 0.60; 95% CI, 0.40–0.89; p = 0.0096), respectively. |
| The most common Grade 3–4 AEs included neutropenia (31% vs 11%), thrombocytopenia (13% vs 8%), and pneumonia (12% vs 11%) in the ibrutinib-venetoclax and ibrutinib-placebo groups, respectively. |
| SAEs were reported in 60% of patients in each group, with treatment-related deaths reported in 2% of patients in each group. |
| Results from the SYMPATICO trial show that ibrutinib-venetoclax vs ibrutinib-placebo improved PFS, with higher ORR and CR rates in patients with R/R MCL, while maintaining a tolerable safety profile. |
Abbreviations: AE, adverse event; BTK, Bruton’s tyrosine kinase; BCL, B-cell lymphoma; CI, confidence interval; CRR, complete response rate; HR, hazard ratio; MCL, mantle cell lymphoma; ORR, overall response rate; PFS, progression-free survival; R/R, relapsed/refractory; SAE, serious adverse event; TTNT, time to next treatment.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
On average, how many patients with chronic lymphocytic leukemia do you see in a month?
